8 assets in Hyper-IgM Syndrome

Therapeutic assets addressing Hyper-IgM Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Hyper-IgM Syndrome	Washington University School of Medicine	P2	CCC (53)
Fludarabine Hyper-IgM Syndrome	Washington University School of Medicine	P2	CCC (53)
Melphalan Hyper-IgM Syndrome	Washington University School of Medicine	P2	CCC (53)
Thiotepa Hyper-IgM Syndrome	Washington University School of Medicine	P2	CCC (53)
cd3/cd19 negative allogeneic hematopoietic stem cells Hyper-IgM Syndrome	Paul Szabolcs	P1/2	CCC (48)
Busulfanum Hyper-IgM Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide Hyper-IgM Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Hyper-IgM Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)